Vaxart Inc., a biotechnology company, is considering implementing a reverse stock split to regain compliance with Nasdaq listing requirements ahead of a June 30, 2025, deadline. The company aims to address its stock price challenges and maintain its Nasdaq listing by potentially adjusting the number of its outstanding shares. This move is part of Vaxart's strategy to support its capital-raising efforts necessary for vaccine development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.